LED light shows cataract safety
A noninvasive LED light therapy for cataracts reported favorable early long‑term safety in follow‑up, suggesting light‑based approaches may complement or delay surgery in selected patients. The early data focus on safety outcomes rather than long‑term visual efficacy, but the result broadens interest in device‑led ophthalmic therapies (optometrytimes.com)
Edinburgh Biosciences’ long-term follow-up reports show participants were monitored for an average of 20 months and as long as 36 months after completing treatment with the REVISYON SDS100 device. (optometrytimes.com) The follow-up phase is an extension of earlier single-arm performance and safety work listed under ClinicalTrials.gov record NCT05396547 (EB‑CE‑01) and the non‑interventional extension registered as NCT07246915 (EB‑CE‑02). (clinicaltrials.gov 1) (clinicaltrials.gov 2) Company presentations and media reports state the program’s pooled datasets include findings from more than 240 participants and that visual function remained stable over the follow-up interval. (eyewire.news) (optometrytimes.com) Edinburgh Biosciences describes the modality as “Photon Protein Modulation” and positions Revisyon as a clinic-delivered, non‑surgical intervention intended for ophthalmologists working in routine practice rather than the operating theatre. (edinburghbiosciences.com) (optometrytimes.com) Commercial-readiness steps cited by the company include completion of the pivotal clinical evaluation in early 2025 and a planned submission of detailed clinical data to a peer‑reviewed journal in the first half of 2026, while the firm secured a £2.3 million loan to support rollout activities. (optometrytimes.com) (opticianonline.net) The regulatory and evidence pathway published on trial registries describes EB‑CE‑02 as an invitation‑only extension study explicitly aimed at assessing long‑term maintenance of safety and performance in mild‑to‑moderate cataract patients. (clinicaltrials.gov)
